Abstract
In hi-tech industries such as Pharma-Biotech, firms are becoming more and more specialized in their innovation capabilities such that it is becoming less and less likely that any one firm is able to independently develop a truly innovative new product. The current research will employ qualitative research methods to investigate two questions: (a) Is the path for the development of radically innovative qualitative different from the development of incrementally innovative products in industries with high technological turbulence such as the Pharma-Biotech industry? (b) Are there any systematic differences in the governance structures employed in the management of interfirm relationships in the development of radical innovations and incremental innovations?
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
